USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20110165159A1
SERIAL NO

13051054

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.

First Claim

See full text

Other Claims data not available

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BIOGEN INC250 BINNEY STREET CAMBRIDGE MA 02142

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Grillo-López, Antonio J Rancho Santa Fe, US 6 220
Leonard, John Carlsbad, US 58 653

Cited Art Landscape

Load Citation

Patent Citation Ranking

  • 54 Citation Count
  • A61K Class
  • 97.22 % this patent is cited more than
  • 14 Age
Citation count rangeNumber of patents cited in rangeNumber of patents cited in various citation count ranges7424023113748323813073422412123001 - 1011 - 2021 - 3031 - 4041 - 5051 - 6061 - 7071 - 8081 - 9091 - 100100 +025050075010001250150017502000225025002750300032503500375040004250

Forward Cite Landscape

Load Citation